Administered as a muco-adhesive buccal tablet, Loramyc is an antifungal agent indicated for the treatment of oropharyngeal candidiasis in immunocompromised patients.
As per the terms of the agreement, BioAlliance is entitled to receive a sum of $3m as an upfront payment from Sosei.
Additionally, BioAlliance is also eligible for further development and sales-based milestones totaling up to a maximum of $18.5m.
BioAlliance will also receive royalties on net sales of the product.
Sosei Group CEO Shinichi Tamura said Loramyc has the potential to become the first treatment in tablet form for oropharyngeal candidiasis in Japan, to provide an important addition to available treatments, and to enhance patients’ compliance and improve their quality of life.